{"entity":{"id":"nct04094688","kind":"trial","name":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","aka":["SOLARIS"],"tldr":"A phase 3 trial of bevacizumab (glioblastoma use), fOLFOX (5-FU, leucovorin, oxaliplatin), leucovorin (folinic acid), fluorouracil (5-FU) and other drugs in colorectal cancer, run by Alliance for Clinical Trials in Oncology, active but no longer recruiting.","summary":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT04094688 by Alliance for Clinical Trials in Oncology, with a registry enrolment figure of 455 participants, started 2019-10-29 and due to reach its primary completion in 2024-07-15. Interventions recorded: Bevacizumab; Oxaliplatin; Leucovorin Calcium; Fluorouracil; Irinotecan Hydrochloride; Irinotecan; Cholecalciferol; Quality-of-Life Assessment; Questionnaire Administration. Conditions listed: Colorectal Adenocarcinoma. Primary outcome: Progression-free Survival (PFS). Colorectal eligibility wording from the registry: \"* Histologically confirmed advanced/metastatic colorectal adenocarcinoma for which metastasectomy is not planned\". Sites: Puerto Rico, United States. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04094688","url":"https://clinicaltrials.gov/study/NCT04094688"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["bevacizumab-glioma","folfox","leucovorin","fluorouracil","irinotecan","folfiri"],"companies":["alliance-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04094688","phase":"3","setting":"Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)","sponsor":"Alliance for Clinical Trials in Oncology","enrolled":455,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04094688/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"}],"company":[{"id":"alliance-oncology","kind":"company","name":"Alliance for Clinical Trials in Oncology","route":"/companies/alliance-oncology/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}